Navigation Links
DOR BioPharma Appoints Brian L. Hamilton, MD, PhD as Chief Medical Officer
Date:3/13/2009

EWING, N.J., March 13 /PRNewswire-FirstCall/ -- DOR BioPharma, Inc. (OTC Bulletin Board: DORB) (DOR or the Company) announced today that it has appointed Brian L. Hamilton, MD, PhD, as Senior Vice President and Chief Medical Officer. Dr. Hamilton is a recognized expert in both the global development of topically active steroids as well as in Graft-versus-Host disease (GVHD) and has had a long and distinguished career of more than 25 years in both academia and industry, most notably at Wyeth and Astra, USA. Dr. Hamilton will lead DOR's clinical affairs, with an emphasis on the execution of its confirmatory Phase 3 clinical trial of orBec(R) (oral beclomethasone dipropionate or BDP) in the treatment of acute GI GVHD.

Dr. Hamilton earned his MD and PhD (Transplantation Immunology) at the University of Washington, Seattle, and trained in Pediatrics, Allergy/Immunology, and Oncology. He began his training in bone marrow transplantation while in medical school, with further training at the Children's Hospital Medical Center, Boston, MA. His academic career, at the University of Washington and the University of Miami, focused on pediatric immunology and bone marrow transplantation. His research focus was in the immunobiology of GVHD in an animal model. He also spent several years as Chief of Immunology at the Children's Hospital, Oakland, CA with a clinical appointment on the Pediatric Bone Marrow Transplant Service at the University of California - San Francisco.

Following his academic career, Dr. Hamilton joined the pharmaceutical industry, initially at Astra, USA in Westborough, MA working on inhaled steroids (Rhinocort Aqua and Pulmicort Turbuhaler) for the treatment of allergic rhinitis and asthma, including three successful new drug applications for these products. He has worked with several pharmaceutical and biotechnology companies including Alkermes in multiple therapeuti
'/>"/>

SOURCE DOR BioPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2008 Financial Results
2. Helix BioPharma Form 20-F Registration Statement Declared Effective by SEC
3. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2008 Financial Results on Friday, March 13, 2009 at 8:30am EDT
4. XTL Biopharmaceuticals Ltd. Extraordinary General Meetings Postponed Until March 18, 2009
5. R&D Spending by U.S. Biopharmaceutical Companies Increases 3 Percent in 2008
6. Keryx Biopharmaceuticals Inc. Announces Receipt of Nasdaq Delisting Notification
7. Frost & Sullivans Biopharmaceuticals Market Briefing to Address the Use of Embryonic Stem Cells
8. Eiger BioPharmaceuticals Raises $7.1 Million A Round
9. Mindset BioPharmaceuticals (USA) Inc Obtains Notice of Allowance for European Patent Related to Use of Insulin Sensitizers in Senile Dementia, Dementia and Memory Loss
10. Mach One Closes on Acquisition of Biopharmaceutical Design & Engineering Firm
11. TechniKroms Biopharmaceutical Equipment Operations to be Integrated With Asahi Kasei Medical
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... , April 17, 2015 /PRNewswire/ - SQI Diagnostics Inc. ... diagnostics company that develops and commercializes proprietary technologies ... announced that it has received approval from the ... 5,126,044 outstanding common share purchase warrants ("the Warrants") ... with the Company,s May 2013 private placement financing. ...
(Date:4/17/2015)... 17, 2015 Global Stem Cells ... Stem Cell Summit 2015 April 27 - 29, 2015 ... developments in all areas of stem cell research including ... cells and regenerative medicine. , The conference will ... well as translational research in stem cell therapies, regenerative ...
(Date:4/16/2015)... South Carolina (PRWEB) April 17, 2015 ... and steam system services, released their newly designed, ... The customer facing website effectively promotes the ... , All the information that a site ... steam system services, company capabilities, industries serviced, the ...
(Date:4/16/2015)... South San Francisco, CA (PRWEB) April 16, 2015 ... it is scheduled to report first quarter results on ... Following the announcement, Cytokinetics’ senior management will host a ... operational and financial results and the company’s outlook for ... webcast and can be accessed from the homepage and ...
Breaking Biology Technology:SQI Diagnostics to Extend Warrant Expiry 2SQI Diagnostics to Extend Warrant Expiry 3Global Stem Cells Group To Join GTCbio Stem Cell and Regenerative Medicine Summit in Boston, April 27-29, 2015 2Global Stem Cells Group To Join GTCbio Stem Cell and Regenerative Medicine Summit in Boston, April 27-29, 2015 3Spirax Sarco website has a new look 2Cytokinetics to Announce First Quarter Results on April 30, 2015 2Cytokinetics to Announce First Quarter Results on April 30, 2015 3
... 8 LifeNet Health, a leading allograft bio-implant company, ... Tendon, both offering new options for ligament reconstruction. ... new bio-medical implants offer sports medicine physicians another alternative ... Tendon can be used in the reconstruction of either ...
... Dec. 8 Building on its flagship,suite of ... the Pyxis(R) MedStation(R) 4000 and an industry-first Performance,Analytics ... help improve medication safety. , ... medication dispensing system,offers new features that can help ...
... in B-Precursor Acute Lymphoblastic Leukemia Show that Blinatumomab is ... , BETHESDA, Md., Dec. 8 ... company developing novel, proprietary antibodies for the treatment of ... data from a phase 2 clinical trial of BiTE(R) ...
Cached Biology Technology:LifeNet Health Introduces New Sports Medicine Bio-Implants 2Cardinal Health Launches Pyxis(R) MedStation(R) 4000; Introduces Industry-First Service to Interpret Dispensing and Infusion Data 2Cardinal Health Launches Pyxis(R) MedStation(R) 4000; Introduces Industry-First Service to Interpret Dispensing and Infusion Data 3Data Presented at ASH Annual Meeting Indicates the Potential of T-Cell Engaging BiTE Antibody Blinatumomab as a Consolidation Treatment for Aggressive Leukemias 2Data Presented at ASH Annual Meeting Indicates the Potential of T-Cell Engaging BiTE Antibody Blinatumomab as a Consolidation Treatment for Aggressive Leukemias 3Data Presented at ASH Annual Meeting Indicates the Potential of T-Cell Engaging BiTE Antibody Blinatumomab as a Consolidation Treatment for Aggressive Leukemias 4Data Presented at ASH Annual Meeting Indicates the Potential of T-Cell Engaging BiTE Antibody Blinatumomab as a Consolidation Treatment for Aggressive Leukemias 5
(Date:3/24/2015)... --  NexID Biometrics LLC, whose spoof-mitigation technology boosts ... the beginning of shipments of version 2.0 of its ... based in Potsdam, N.Y. , is ... began here today at the Walter E. Washington Convention ... SDK boosts the accuracy rate range to 96.5 to ...
(Date:3/23/2015)... March 23, 2015 SoundView Technology Group issues a ... NXTD ) Wocket smart wallet. SoundView was one of the ... their experience with the Wocket in multiple scenarios and outlets. ... Foods and other retailers, making both debit and credit card ... also says, "If the company meets their plans in 2015, ...
(Date:3/23/2015)... 2015  In the 2014 fiscal year, irs.gov recorded ... This figure accounts for a fraction of the estimated ... Report, exceeds $11 billion globally. The polygraph has traditionally ... has occurred. Investor Mark Saint Juste along ... Paolella partnered to administer the test in a ...
Breaking Biology News(10 mins):NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 3Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 4Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3
... work and scientific adventure, marine explorers from more than ... Laboratory (MBL), today delivered the first global Census of ... and hides in the world,s oceans. In one of ... scientists spent over 9,000 days at sea on more ...
... survived for more than 400 million years, the horseshoe ... overharvest and habitat destruction. However, climatic changes may,also play ... how sensitive horseshoe crab populations are to natural climate ... Molecular Ecology . The horseshoe crab is ...
... Jerusalem, October 4, 2010 Researchers at the Hebrew University ... body that play a key role in controlling bone density, ... drug for prevention and treatment of osteoporosis and other bone ... researchers have just been published in the American journal ...
Cached Biology News:MBL scientists reveal findings of World Ocean Microbe Census 2MBL scientists reveal findings of World Ocean Microbe Census 3Climate change affects horseshoe crab numbers 2Hebrew University research holds promise for development of new osteoporosis drug 2